Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - o
16910
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Engineered Muc
o
sal-Associated Invariant T (MAIT) Cells and Methods of Making and Using Thereof (UCLA Case No. 2024-055)
UCLA researchers in the Department
o
f Microbiology Immunology and Molecular Genetics have developed a novel platform and methodology for the production of mucosal-associated invariant T (MAIT) cells for therapeutic use in infectious diseases, autoimmune disorders, and cancer. BACKGROUND: Mucosal-associated invariant T (MAIT) cells are a subset of...
Published: 7/31/2025
|
Inventor(s):
Lili Yang
Keywords(s):
Category(s):
Therapeutics >
O
ncology
,
Therapeutics > Infecti
o
us Diseases
,
Therapeutics > Immun
o
logy And Immunotherapy
,
Therapeutics > Aut
o
immune
Telaprevir-derived Enter
o
virus D68 2A protease inhibitors are antiviral drug candidates
Published data f
o
r lead compounds, the telaprevir-derived 2Apro inhibitor Jun11762 and others, demonstrate substantial improvement over Telaprevir in plaque assay. See link to paper below. Invention Summary: The genus Enterovirus of Picornaviridae contains many significant pathogens related to human and mammalian diseases. Enterovirus D68...
Published: 7/31/2025
|
Inventor(s):
Jun Wang
,
Bin Tan
,
Prakash Jadhav
,
Kan Li
Keywords(s):
Antiviral
,
Small m
o
lecules
Category(s):
Techn
o
logy Classifications > Healthcare & Life Sciences
,
Techn
o
logy Classifications > Infectious Disease
,
Techn
o
logy Classifications > Therapeutics
Fumaramide SARS-C
o
V-2 papain-like protease inhibitors are antiviral drug candidates
Published data f
o
r lead compound, the fumaramide PLpro inhibitor Jun13728, demonstrate potent inhibition of SARS-CoV2 variants including nirmatrelvir-resistant mutant (light blue). Link to paper below. Invention Summary: The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for...
Published: 7/31/2025
|
Inventor(s):
Jun Wang
,
Bin Tan
,
Prakash Jadhav
,
Ahmadullah Ansari
,
Francesc Ruiz Figueras
,
Edward Arn
o
ld
Keywords(s):
Category(s):
Techn
o
logy Classifications > Healthcare & Life Sciences
,
Techn
o
logy Classifications > Therapeutics
M
o
dular protein degradation platform bypassing ubiquitination
Backgr
o
und Targeted protein degradation is rapidly emerging as a powerful therapeutic approach for eliminating disease-causing proteins in cancer, neurodegenerative conditions, autoimmune disorders, and viral infections. By removing, rather than inhibiting, harmful proteins, this strategy enables direct and sustained therapeutic effects....
Published: 7/31/2025
|
Inventor(s):
Andreas Mat
o
uschek
,
Amit Kumar Singh Gautam
,
Car
o
line Davis
,
L
o
gan Spaller
Keywords(s):
Category(s):
Life sciences > Therapeutics > Synthetic bi
o
logy
,
Life sciences > Research t
o
ols > Tool/assay/screening platform
Micr
o
bial Functions and Molecules to Promote the Beneficial Effects of the Ketogenic Diet (UCLA Case No. 2022-122)
UCLA researchers in the Department
o
f Integrative Biology and Physiology have successfully mapped the functional gut microbiota and specific metabolic molecules that promote relief from epilepsy through the ketogenic diet. BACKGROUND: Research supported by the National Institutes of Health has shown that the gut microbiome has tremendous impact on...
Published: 7/31/2025
|
Inventor(s):
Elaine Hsia
o
Keywords(s):
Category(s):
Therapeutics > CNS and Neur
o
logy
Bi
o
compatible photoenzymatic system for selective C–H fluorination
Backgr
o
und C–H fluorination plays a central role in pharmaceutical and agrochemical synthesis, as the introduction of fluorine often enhances a molecule's metabolic stability, potency, and bioavailability. Over 20% of approved drugs contain fluorinated functional groups, underscoring the demand for efficient and selective fluorination methods....
Published: 7/31/2025
|
Inventor(s):
Yi Lu
,
Yu Zh
o
u
Keywords(s):
Category(s):
Life sciences > Metab
o
lic engineering
O
PG153-based vaccine for targeted mpox immunization
Backgr
o
und The global re-emergence of monkeypox virus (MPXV) has created a critical need for effective and well-tolerated vaccines to prevent infection, limit disease severity, and reduce transmission. As an orthopoxvirus related to smallpox, mpox presents a unique public health challenge, especially for immunocompromised populations. Current...
Published: 7/31/2025
|
Inventor(s):
Jas
o
n McLellan
,
Ling Zh
o
u
,
Emily Rundlet
,
Emanuele Andrean
o
,
Rin
o
Rappuoli
,
Ida Paciell
o
,
Giulia Realini
,
Federica Perr
o
ne
Keywords(s):
Category(s):
Life sciences > Therapeutics > Vaccines
Irreversible DGKα inhibit
o
rs for enhanced T‑cell activation in cancer immunotherapy
Backgr
o
und Cancer immunotherapy seeks to harness the immune system to target and eliminate malignant cells. However, immune suppression within the tumor microenvironment poses a major challenge, blunting T-cell activation and allowing cancer cells to evade immune detection. Diacylglycerol Kinase α (DGKα) is a key enzyme that suppresses...
Published: 7/31/2025
|
Inventor(s):
Ku-Lung Hsu
,
Minhaj Shaikh
,
Adam Libby
,
Surya Prav
o
Mookherjee
Keywords(s):
Category(s):
Life sciences > Therapeutics > F
o
rmulation
Quin
o
line-derived SARS-CoV-2 papain-like protease inhibitors are oral antiviral drug candidates
A lead c
o
mpound, the quinoline-derived PLpro inhibitor Jun13296, demonstrates substantial protection against SARS-CoV-2 infection and adverse clinical outcomes. Invention Summary: The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for research to support pandemic preparedness...
Published: 7/31/2025
|
Inventor(s):
Jun Wang
,
Prakash Jadhav
,
Bin Tan
,
Ha
o
zhou Tan
Keywords(s):
Antiviral
Category(s):
Techn
o
logy Classifications > COVID-19
,
Techn
o
logy Classifications > Healthcare & Life Sciences
,
Techn
o
logy Classifications > Infectious Disease
,
Techn
o
logy Classifications > Therapeutics
Specific inhibit
o
rs to mitigate mu opioid‐induced side‐effects without compromising analgesia
Preliminary data sh
o
ws that the inhibitor significantly mitigates morphine tolerance in a mouse study Invention Summary: Mu opioids such as morphine and fentanyl are commonly used for pain management but can lead to tolerance, addiction, and opioid use disorder. Current therapeutic solutions for these adverse conditions include buprenorphine,...
Published: 7/31/2025
|
Inventor(s):
Yingxian Pan
Keywords(s):
Category(s):
Techn
o
logy Classifications > Healthcare & Life Sciences
,
Techn
o
logy Classifications
,
Techn
o
logy Classifications > Therapeutics
1
2
3
4
5
6
7
8
9
10
...